The subject received cytotoxic chemotherapy within the past  weeks ( weeks for nitrosoureas) of the planned surgery date
At least  weeks from previous chemotherapy;  weeks from nitrosoureas
A minimum of  weeks must have elapsed from the last dose of nitrosoureas.
Patient received chemotherapy within  weeks prior to initiation of treatment with Toca  ( weeks for nitrosoureas).
Chemotherapy: nitrosoureas (At least  weeks since last dose of nitrosoureas prior to first dose of tazemetostat)
 weeks from nitrosoureas
 weeks from nitrosoureas
Patients must be at least  weeks from previous chemotherapy;  weeks from nitrosoureas
Chemotherapy: nitrosoureas (At least  weeks since last dose of nitrosoureas prior to first dose of tazemetostat)
Chemotherapy: nitrosoureas At least  weeks
Chemotherapy administered within  weeks (except  weeks for nitrosoureas,  weeks for an implanted nitrosoureas wafer, and  week from metronomic chemotherapy, like daily temozolomide and etoposide) prior to Day  of study treatment, unless the subject has recovered from all expected toxicities from the chemotherapy.
 weeks from nitrosoureas
No chemotherapy or investigational agent for at least  weeks prior to the start of SL-, with at least  weeks of elapsed time from last dose of nitrosoureas.
Has the subject received cytotoxic chemotherapy within the past  weeks ( weeks for nitrosoureas) of the planned date of vector injection?
 days from administration of nitrosoureas
Nitrosoureas:  weeks
Nitrosoureas:  weeks
No chemotherapy within  weeks of first dose of SGI- (minimum of  weeks for nitrosoureas and  weeks for bone marrow transplantation) with the exception of hydroxyurea which will be allowed during course  of treatment.
